News & Updates

Treatment with the next-generation anti-TNFα antibody yields marked improvements in the signs and symptoms of rheumatoid arthritis in patients with inadequate response to methotrexate (MTX), while having an acceptable safety profile, as shown in the phase II/III OHZORA trial.

Taking aspirin daily appears to do nothing in terms of reducing the risk of cutaneous melanoma in older individuals, according to a study.

Treatment with intravenous or oral solithromycin is well-tolerated and leads to clinical improvement in most children and adolescents with community-acquired bacterial pneumonia (CABP), results of a recent study have shown.

The serine protease inhibitor camostat mesylate does not appear to be an effective antiviral agent in patients with early-phase COVID-19, having failed to stop SARS-CoV-2 in its tracks in a phase II trial.